Drug Trial Radar · NCT04344717
Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Dec 20, 2020
Primary completion
Sep 30, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Short bowel syndrome (SBS) is defined as a loss of function of the small intestine resulting in a malabsorptive disorder. In SBS, oral drug absorption may be altered due to extensive intestinal resection. It remains unclear to what extent apixaban exposure is impacted in SBS.Therefore this study tries to investigate the pharmacokinetics (PK) of apixaban in adult patients with SBS requiring long-term parenteral nutrition (PN).
Conditions
- Short Bowel Syndrome
- Anticoagulation
Interventions
Apixaban single doseDrug
A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured
Apixaban steady-stateDrug
Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in Cmax of apixaban between SBS and patients with a normal gastrointestinal tractTime frame: Through study completion, an average of 1.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospitals Leuven
Leuven, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.